Aclaris Therapeutics, Inc. (ACRS) Debt Components
- 2021-06-30: Long-term DebtUSD $10.73M; Line of Credit Facility, Maximum Borrowing CapacityUSD (m).
- 2021-03-31: Long-term DebtUSD $10.69M; Line of Credit Facility, Maximum Borrowing CapacityUSD (m).
- 2020-12-31: Long-term DebtUSD $10.65M; Line of Credit Facility, Maximum Borrowing CapacityUSD (m).
- 2020-09-30: Long-term DebtUSD $10.61M; Line of Credit Facility, Maximum Borrowing CapacityUSD (m).
Aclaris Therapeutics, Inc. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt USD | Line of Credit Facility, Maximum Borrowing Capacity USD |
|---|---|---|
| 2021-06-30 | $10.73M | (m) |
| 2021-03-31 | $10.69M | (m) |
| 2020-12-31 | $10.65M | (m) |
| 2020-09-30 | $10.61M | (m) |
| 2020-06-30 | $10.57M | (m) |
| 2020-03-31 | $10.57M | (m) |
| 2019-09-30 | $29.93M | (m) |
| 2019-06-30 | $29.92M | (m) |
| 2019-03-31 | $29.92M | (m) |
| 2018-12-31 | $29.91M | (m) |
| 2018-10-15 | (m) | $65.00M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |